Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Top-Line Results Expected in First Half of 2017
Novan, Inc. today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing SB208 as a broad-spectrum anti-fungal gel for the treatment of infections of the skin and nails, including athlete’s foot and onychomycosis.